Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus,...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-07, Vol.25 (7), p.1283-1293 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1293 |
|---|---|
| container_issue | 7 |
| container_start_page | 1283 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | Polo, V. Besse, B. |
| description | Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus, progression-free and overall survival with minimal toxicity and maintenance or improvement of quality of life of patients. We review here clinical trials evaluating continuation maintenance therapy or switch maintenance therapy in locally advanced or metastatic NSCLC, to highlight the achievements made and critical issues faced. Based on the available results and limitations of these trials, maintenance therapy should be considered a good treatment strategy for a limited subgroup of patients. Maintenance therapy should be personalised according to the characteristics of patients and their disease, taking into account the data available for the agents used in this setting. |
| doi_str_mv | 10.1093/annonc/mdt529 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1551828695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419366839</els_id><sourcerecordid>1551828695</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-5ef05fc23ab105d0cc7f69f1425818dbd0145bd832bf2b92351382ac217dee23</originalsourceid><addsrcrecordid>eNp1kEtP3DAQgK0KVBbaY6_IFySQSLGdOGv3UqEVL2nbHop6tRx7smuaOIvtgPj39SoLPXEazeib14fQF0q-UiLLC-394M1FbxNn8gOaUV7LQpCK7qEZkaws5rysDtBhjA-EkFoy-REdsKrktJRihv7-0M4n8NobwDEFnWDlIGLnc6ZXgO_-4LygiL3uusJA1-Fu9Ctstg0Bn_78vVguzr5t-ee1M2u80cmBT_EcP7u03hVtGFfx-ye03-ouwuddPEL311f3i9ti-evmbnG5LExFSSo4tIS3hpW6oYRbYsy8rWVLK8YFFbaxhFa8saJkTcua_GJ-RTBtGJ1bAFYeodNp7CYMjyPEpHoXt5drD8MYFeWcCiZqyTNaTKgJQ4wBWrUJrtfhRVGitnrVpFdNejN_vBs9Nj3YN_rVZwZOdoCORndtyJpc_M-JmtaSVJmbTxxkD08OgoomazNgXQCTlB3cOyf8AwbzmDs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1551828695</pqid></control><display><type>article</type><title>Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Polo, V. ; Besse, B.</creator><creatorcontrib>Polo, V. ; Besse, B.</creatorcontrib><description>Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus, progression-free and overall survival with minimal toxicity and maintenance or improvement of quality of life of patients. We review here clinical trials evaluating continuation maintenance therapy or switch maintenance therapy in locally advanced or metastatic NSCLC, to highlight the achievements made and critical issues faced. Based on the available results and limitations of these trials, maintenance therapy should be considered a good treatment strategy for a limited subgroup of patients. Maintenance therapy should be personalised according to the characteristics of patients and their disease, taking into account the data available for the agents used in this setting.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdt529</identifier><identifier>PMID: 24351398</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - physiopathology ; continuation maintenance ; early second line ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Lung Neoplasms - physiopathology ; Medical sciences ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; non-small-cell lung cancer ; Pharmacology. Drug treatments ; Pneumology ; Quality of Life ; switch maintenance ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Annals of oncology, 2014-07, Vol.25 (7), p.1283-1293</ispartof><rights>2013 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><rights>The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-5ef05fc23ab105d0cc7f69f1425818dbd0145bd832bf2b92351382ac217dee23</citedby><cites>FETCH-LOGICAL-c410t-5ef05fc23ab105d0cc7f69f1425818dbd0145bd832bf2b92351382ac217dee23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28616904$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24351398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Polo, V.</creatorcontrib><creatorcontrib>Besse, B.</creatorcontrib><title>Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus, progression-free and overall survival with minimal toxicity and maintenance or improvement of quality of life of patients. We review here clinical trials evaluating continuation maintenance therapy or switch maintenance therapy in locally advanced or metastatic NSCLC, to highlight the achievements made and critical issues faced. Based on the available results and limitations of these trials, maintenance therapy should be considered a good treatment strategy for a limited subgroup of patients. Maintenance therapy should be personalised according to the characteristics of patients and their disease, taking into account the data available for the agents used in this setting.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - physiopathology</subject><subject>continuation maintenance</subject><subject>early second line</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - physiopathology</subject><subject>Medical sciences</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>non-small-cell lung cancer</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Quality of Life</subject><subject>switch maintenance</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtP3DAQgK0KVBbaY6_IFySQSLGdOGv3UqEVL2nbHop6tRx7smuaOIvtgPj39SoLPXEazeib14fQF0q-UiLLC-394M1FbxNn8gOaUV7LQpCK7qEZkaws5rysDtBhjA-EkFoy-REdsKrktJRihv7-0M4n8NobwDEFnWDlIGLnc6ZXgO_-4LygiL3uusJA1-Fu9Ctstg0Bn_78vVguzr5t-ee1M2u80cmBT_EcP7u03hVtGFfx-ye03-ouwuddPEL311f3i9ti-evmbnG5LExFSSo4tIS3hpW6oYRbYsy8rWVLK8YFFbaxhFa8saJkTcua_GJ-RTBtGJ1bAFYeodNp7CYMjyPEpHoXt5drD8MYFeWcCiZqyTNaTKgJQ4wBWrUJrtfhRVGitnrVpFdNejN_vBs9Nj3YN_rVZwZOdoCORndtyJpc_M-JmtaSVJmbTxxkD08OgoomazNgXQCTlB3cOyf8AwbzmDs</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Polo, V.</creator><creator>Besse, B.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140701</creationdate><title>Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?</title><author>Polo, V. ; Besse, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-5ef05fc23ab105d0cc7f69f1425818dbd0145bd832bf2b92351382ac217dee23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - physiopathology</topic><topic>continuation maintenance</topic><topic>early second line</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - physiopathology</topic><topic>Medical sciences</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>non-small-cell lung cancer</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Quality of Life</topic><topic>switch maintenance</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Polo, V.</creatorcontrib><creatorcontrib>Besse, B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Polo, V.</au><au>Besse, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>25</volume><issue>7</issue><spage>1283</spage><epage>1293</epage><pages>1283-1293</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus, progression-free and overall survival with minimal toxicity and maintenance or improvement of quality of life of patients. We review here clinical trials evaluating continuation maintenance therapy or switch maintenance therapy in locally advanced or metastatic NSCLC, to highlight the achievements made and critical issues faced. Based on the available results and limitations of these trials, maintenance therapy should be considered a good treatment strategy for a limited subgroup of patients. Maintenance therapy should be personalised according to the characteristics of patients and their disease, taking into account the data available for the agents used in this setting.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>24351398</pmid><doi>10.1093/annonc/mdt529</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-07, Vol.25 (7), p.1283-1293 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1551828695 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - physiopathology continuation maintenance early second line Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - physiopathology Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) non-small-cell lung cancer Pharmacology. Drug treatments Pneumology Quality of Life switch maintenance Tumors Tumors of the respiratory system and mediastinum |
| title | Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A35%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintenance%20strategies%20in%20stage%20IV%20non-small-cell%20lung%20cancer%20(NSCLC):%20in%20which%20patients,%20with%20which%20drugs?&rft.jtitle=Annals%20of%20oncology&rft.au=Polo,%20V.&rft.date=2014-07-01&rft.volume=25&rft.issue=7&rft.spage=1283&rft.epage=1293&rft.pages=1283-1293&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdt529&rft_dat=%3Cproquest_cross%3E1551828695%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1551828695&rft_id=info:pmid/24351398&rft_els_id=S0923753419366839&rfr_iscdi=true |